InsiderTrades

Form 4 for RPRX Royalty Pharma plc

Accepted 2025-11-07 00:00:00 ET · period of report 2025-11-05 · accession 0001838139-25-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2025-11-07 2025-11-07 RPRX Urist Marshall EVP, Research, Investments C - Cnv Deriv $0.00 +160.0K 206.7K +343% $0
D 2025-11-07 2025-11-05 RPRX Urist Marshall EVP, Research, Investments A - Grant $0.00 +4,626 43.9K +12% $0
DI 2025-11-07 2025-11-07 RPRX Urist Marshall EVP, Research, Investments C - Cnv Deriv $0.00 -16.0K 247.4K -6% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Ordinary Shares 2025-11-07 C A 160,000 $0.00 206,667 I — —
2 Common Class A Ordinary Shares 2025-11-05 A A 4,626 $0.00 43,882 D By Sandy Lamm LLC — — (F1) Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
3 Derivative LP interests in RPI US Partners 2019, LP 2025-11-07 C D 16,000 $0.00 247,412 I By Sandy Lamm LLC $0.00 · — to — 160,000 Class A Ordinary Shares (F3) Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.